支持新兴成年糖尿病患者(SEAD)项目:一种基于成人的真实世界临床模式,可改善医疗服务不足的1型糖尿病年轻成人的住院率、糖尿病技术使用率和血糖结局
SEAD项目整合到常规内分泌诊疗中,纵向队列研究纳入497例1型糖尿病年轻成人(SEAD组332例,常规内分泌诊疗组165例),采用倾向加权分析。SEAD组基线HbA1c>9%者住院发生率降低64%(HR 0.36 [0.13, 0.98]),公共保险者降低74%(HR 0.26 [0.07, 0.90]),自动胰岛素输送使用率较高(HR 1.51 [0.83, 2.77]),HbA1c改善幅度更大。
要点
- SEAD组基线HbA1c>9%的年轻成人住院发生率降低64%(HR 0.36 [0.13, 0.98])。
- SEAD组公共保险者住院发生率降低74%(HR 0.26 [0.07, 0.90])。
- SEAD组自动胰岛素输送使用率为1.5倍(HR 1.51 [0.83, 2.77]),HbA1c年降幅大于常规诊疗组。
核心结论
- SEAD项目可改善医疗服务不足的1型糖尿病年轻成人的临床结局,尤其对公共保险者和高基线HbA1c者。
- 作者认为,在1型糖尿病高风险年轻成人进入成人诊疗时早期干预,可能减少短期和长期结局的不公平。
研究设计与样本
- 纵向队列研究,前瞻性收集4年数据,比较SEAD组与常规内分泌诊疗组的年轻成人1型糖尿病患者。
- 共纳入497例1型糖尿病年轻成人,SEAD组332例,常规内分泌诊疗组165例;平均年龄25岁,27%为非西班牙裔黑人,46%为西班牙裔,49%持有公共保险,平均HbA1c 9.2%。
- 采用倾向加权分析校正基线特征差异,并用多变量回归和Cox比例风险模型评估结局随时间的变化。
- 主要结局包括住院发生率、糖尿病技术使用率和HbA1c年变化。
主要发现
- 基线HbA1c>9%者中,SEAD组较常规诊疗组住院发生率降低64%(HR 0.36 [0.13, 0.98])。
- 公共保险者中,SEAD组较常规诊疗组住院发生率降低74%(HR 0.26 [0.07, 0.90])。
- SEAD组较常规诊疗组自动胰岛素输送使用率为1.5倍(HR 1.51 [0.83, 2.77])。
- SEAD组HbA1c年改善为-0.37%/年([-0.59, -0.15]),常规诊疗组为-0.26%/年([-0.58, 0.05]),SEAD组改善幅度更大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Underserved young adults (YA) with type 1 diabetes (T1D) experience the worst outcomes across the life span. We developed and integrated the Supporting Emerging Adults with Diabetes (SEAD) program into routine endocrinology care to address unmet social and medical challenges. RESEARCH DESIGN AND METHODS: This study was designed as a longitudinal cohort study, with prospective data collection over 4 years on YA in SEAD compared with usual endocrine care. We used propensity-weighted analysis to account for differences in baseline characteristics, and multivariate regression and Cox proportional hazard models to evaluate change in outcomes over time. Primary outcomes included incidence of hospitalizations, diabetes technology uptake, and annual change in HbA1c levels. RESULTS: We included 497 YA with T1D in SEAD (n = 332) and usual endocrine care (n = 165); mean age 25 years, 27% non-Hispanic Black, 46% Hispanic, 49% public insurance, mean HbA1c 9.2%. Comparing YA in SEAD versus usual care, 1) incidence of hospitalizations was reduced by 64% for baseline HbA1c >9% (HR 0.36 [0.13, 0.98]) and 74% for publicly insured (HR 0.26 [0.07, 0.90]); 2) automated insulin delivery uptake was 1.5-times higher (HR 1.51 [0.83, 2.77]); and 3) HbA1c improvement was greater (SEAD, -0.37% per year [-0.59, -0.15]; usual care, -0.26% per year [-0.58, 0.05]). CONCLUSIONS: SEAD meaningfully improves clinical outcomes in underserved YA with T1D, especially for publicly insured and high baseline HbA1c levels. Early intervention for at-risk YA with T1D as they enter adult care could reduce inequity in short and long-term outcomes.
引用
- Agarwal S, Mathias P, Schechter C, et al. The Supporting Emerging Adults With Diabetes (SEAD) Program: An Adult-Based Real-World Clinical Model That Improves Hospitalizations, Diabetes Technology Uptake, and Glycemic Outcomes in Underserved Young Adults With Type 1 Diabetes. Diabetes Care. 2024. PMID: 39288191. doi:10.2337/dc24-1346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。